NETs are rare,
heterogeneous group of neoplasm presented as chronic oncologic disease.
Somatostatin analogue is the standard first line systemic therapy for mainly
hormone control.
No
standard second line systemic treatment is available except everolimus
which has no reported complete response.
PRRT is an
innovative molecular targeted treatment based on theragnostic concept for well
differentiated NETs. We presented here a 63-year-old lady with grade 1 NET of
rectum with lymphnodal and liver metastasis.
No comments:
Post a Comment